

## DAFTAR PUSTAKA

- Afzal, S., Muhammad Nadeem Hassan, Ullah, S., Abbas, H., Tawakkal, F., & Mohsin Ahmad Khan. (2022). Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications. *Frontiers in Molecular Biosciences*, 9. <https://doi.org/10.3389/fmolb.2022.783450>
- Ashariati, A. (2019). Manajemen Kanker Payudara Komprehensif. *Journal of Chemical Information and Modeling*, 53(9), 1689–1699. [http://repository.unair.ac.id/96210/2/Manajemen Kanker Payudara Komprehensif.pdf](http://repository.unair.ac.id/96210/2/Manajemen_Kanker_Payudara_Komprehensif.pdf)
- Benz CC. Impact of aging on the biology of breast cancer. *Crit Rev Oncol Hematol*. 2008;66(1):65–74. <https://doi.org/10.1016/j.critrevonc.2007.09.001>.
- Bhushan, A., Gonsalves, A., & Menon, J. U. (2021). Current State of Breast Cancer Diagnosis, Treatment, and Theranostics. *Pharmaceutics*, 13(5), 723–723. <https://doi.org/10.3390/pharmaceutics13050723>
- Carlson, R. W. (2005). The history and mechanism of action of fulvestrant. *Clinical Breast Cancer*, 6(SUPPL. 1), S5. <https://doi.org/10.3816/CBC.2005.s.008>
- Chen J., Lindblom A. Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p. *Clin. Genet*. 2001;57:394–397. doi: 10.1034/j.1399-0004.2000.570511.x. [PubMed] [CrossRef] [Google Scholar]
- Coates, A. S., Colleoni, M., & Goldhirsch, A. (2012). Is adjuvant chemotherapy useful for women with luminal a breast cancer. *J Clin Oncol*, 30(12), 1260-1263.

Corso G., Intra M., Trentin C., Veronesi P., Galimberti V. CDH1 germline mutations and hereditary lobular breast cancer. *Fam. Cancer*. 2016;15:215–219. doi: 10.1007/s10689-016-9869-5.

Corso G., Veronesi P., Sacchini V., Galimberti V. Prognosis and outcome in CDH1-mutant lobular breast cancer. *Eur. J. Cancer Prev.* 2018;27:237–238. doi: 10.1097/CEJ.0000000000000405.

Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., ... Narod, S. A. (2007). Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. *Clinical Cancer Research*, 13(15), 4429–4434. <https://doi.org/10.1158/1078-0432.ccr-06-3045>

Direktorat Jenderal Pelayanan Kesehatan. (2023). Retrieved April 28, 2024, from [Kemkes.go.id](https://www.kemkes.go.id) website: [https://yankes.kemkes.go.id/view\\_artikel/2169/pansitopenia](https://yankes.kemkes.go.id/view_artikel/2169/pansitopenia)

Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis*. 2018;5(2):77–106. <https://doi.org/10.1016/j.gendis.2018.05.001>.

Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. *Global Cancer Observatory: Cancer Today*. International Agency for Research on Cancer; Lyon, France: 2020.

Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., Im, S. A., Krug, D., Kunz, W. G., Loi, S., Penault-Llorca, F., Ricke, J., Robson, M., Rugo, H. S., Saura,

C., ... Harbeck, N. (2021). ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆. *Annals of Oncology*, 32(12), 1475–1495. <https://doi.org/10.1016/j.annonc.2021.09.019>

Globocan. (2020). International agency for research on cancer (IARC) 2021. Estimated number of deaths in 2020 worldwide, Indonesia, female, all ages. [https://gco.iarc.fr/today/onlineanalysispie?v=2020&mode=cancer&mode\\_population=continents&population=900&populations=900\\_360&key=total&sex=2&cancer=39&type=1&statistic=5&prevalence=0&population\\_group=0&ages\\_group%5B%5D=0&ages\\_group%5B%5D=17&nb\\_items=7&group\\_cancer=0&include\\_nmsc=0&include\\_nmsc\\_other=1&half\\_pie=0&donut=0#collapseby\\_country.%20Diakses%2029%20Juni%202021](https://gco.iarc.fr/today/onlineanalysispie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900_360&key=total&sex=2&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=0&include_nmsc=0&include_nmsc_other=1&half_pie=0&donut=0#collapseby_country.%20Diakses%2029%20Juni%202021).

Greenblatt, K., & Karam Khaddour. (2022, November 28). Trastuzumab. Retrieved December 7, 2023, from Nih.gov website: <https://www.ncbi.nlm.nih.gov/books/NBK532246/>

Gulay Mart, Malkan, U. Y., & Yahya Buyukasik. (2022). Determination of etiology in patients admitted due to isolated leukopenia. *Medicine*, 101(33), e30116–e30116. <https://doi.org/10.1097/md.00000000000030116>

Hamdi, M., Würinger, E., Schlenz, I., & Kuzbari, R. (2005). Anatomy of the breast: A clinical application. Vertical Scar Mammoplasty, 1–8. [https://doi.org/10.1007/3-540-27218-6\\_1](https://doi.org/10.1007/3-540-27218-6_1)

- Han, Y., Li, Q., Xu, B. H., Zhang, P., Yuan, P., Wang, J. Y., ... Fan, Y. (2015). Adjuvant chemotherapy may improve survival of patients with luminal A breast cancer and positive lymph nodes. *Genetics and Molecular Research*, 14(3), 8563–8573. <https://doi.org/10.4238/2015.july.31.4>
- Herr, D., Wischnewsky, M., Ralf Joukhadar, Chow, O., Janni, W., Leinert, E., ... Achim Wöckel. (2019). Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study. *PloS One*, 14(7), e0218434–e0218434. <https://doi.org/10.1371/journal.pone.0218434>
- Hormone Therapy for Breast Cancer Fact Sheet - NCI. (2022). Cancer.Gov. <https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet>
- KEMENKES RI. (2016). PERATURAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR 25 TAHUN 2016 TENTANG RENCANA AKSI NASIONAL KESEHATAN LANJUT USIA TAHUN 2016-2019. In K. K. Indonesia. Jakarta: Menteri Kesehatan Republik Indonesia.
- Koh, J., & Kim, M. J. (2019). Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage. *Korean Journal of Radiology*, 20(1), 69. <https://doi.org/10.3348/KJR.2018.0231>
- Lagopoulos, M. (2007). Anatomy of the breast. *Interventional Ultrasound of the Breast*, 1(5), 11–22. <https://doi.org/10.55927/ijsmr.v1i5.4394>
- Li, S., Bao, C., Huang, L., & Wei, J.-F. (2022). Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists' Perspective.

Journal of Clinical Medicine, 11(20), 6021–6021.

<https://doi.org/10.3390/jcm11206021>

Li, Y., & Ma, L. (2020). Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis. *World Journal of Surgical Oncology*, 18(1). <https://doi.org/10.1186/s12957-020-02089-y>

María Florencia Mercogliano, Bruni, S., Florencia Luciana Mauro, & Schillaci, R. (2023). Emerging Targeted Therapies for HER2-Positive Breast Cancer. *Cancers*, 15(7), 1987–1987. <https://doi.org/10.3390/cancers15071987>

Masoud, V., & Pagès, G. (2017). Targeted therapies in breast cancer: New challenges to fight against resistance. *World Journal of Clinical Oncology*, 8(2), 120–134. <https://doi.org/10.5306/wjco.v8.i2.120>

Nathan, M. R., & Schmid, P. (2017). A Review of Fulvestrant in Breast Cancer. *Oncology and Therapy*, 5(1), 17–29. <https://doi.org/10.1007/s40487-017-0046-2>

Olson, D., Taylor, J., Willis, K., Hensley, K., Allred, S., Zaval, M., Kulukian, A. (2023). HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer. *Cancer Research Communications*, 3(9), 1927–1939. <https://doi.org/10.1158/2767-9764.crc-23-0302>

Radhakrishna Selvi, Sangeet Kumar Agarwal, Parikh, P. M., Kaur, K., Shikha Panwar, Sharma, S., Sud, S. (2018). Role of magnetic resonance imaging in breast cancer management. *South Asian Journal of Cancer*, 07(02), 069–071. [https://doi.org/10.4103/sajc.sajc\\_104\\_18](https://doi.org/10.4103/sajc.sajc_104_18)

- Schneble, E., Jinga, D.-C., George, J., Peoples, E., & Jinga, D. (2015). Breast Cancer Immunotherapy. *Mædica*, 10(2), 185. [/pmc/articles/PMC5327815/](https://pubmed.ncbi.nlm.nih.gov/31527815/)
- Sheikh, M. S., & Satti, S. A. (2021). The emerging CDK4/6 inhibitor for breast cancer treatment. *Molecular and Cellular Pharmacology*, 13(3), 9–12.  
Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896653/>
- Simon, A., & Robb, K. (2022). Breast Cancer. *Cambridge Handbook of Psychology, Health and Medicine, Second Edition*, 577–580.  
<https://doi.org/10.1017/CBO9780511543579.131>
- Stanisławek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies— An Updated Review. 1–30.
- Wang, R., Wang, R., Tian, J., Wang, J., Tang, H., Wu, T., & Wang, H. (2022). BTG2 as a tumor target for the treatment of luminal A breast cancer. *Experimental and Therapeutic Medicine*, 23(5).  
<https://doi.org/10.3892/etm.2022.11269>
- WHO. (2023). Breast cancer. <https://doi.org/https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
- Wynn, C. S., & Tang, S.-C. (2022). Anti-HER2 therapy in metastatic breast cancer: many choices and future directions. *Cancer and Metastasis Reviews/Cancer Metastasis Reviews*, 41(1), 193–209.  
<https://doi.org/10.1007/s10555-022-10021-x>